Go to Top

We discover and develop novel, "best-in-class" inhibitors of CYP17, a validated metalloenzyme involved in prostate cancer.




William R. Moore, Ph.D.
President, CEO and Director

William  Moore, Ph.D.  is a founder of Innocrin Pharmaceuticals. Dr. Moore leads the company following five years of directing the CYP17 lyase inhibitor program as Chief Scientific Officer at Viamet Pharmaceuticals.  Dr. Moore has more than 25 years of pharmaceutical and biotechnology experience, 15 of those at the C-Level. Prior responsibilities at Marion Merrell Dow, Axys Pharmaceuticals and Locus Pharmaceuticals encompassed technology innovation, intellectual property, business development, fundraising and all aspects of research and development.  Dr. Moore has a Ph.D. degree in chemistry from Brown University and was a Winston Fellow and faculty member at Cornell University Medical College prior to his industrial career.


Edwina Baskin-Bey, M.D.
Chief Medical Officer

Dr. Edwina Baskin-Bey leads the seviteronel clinical development programs. Dr. Baskin-Bey has strong experience with oncology drug development, in particular hormonal therapies for the treatment of prostate cancer. Immediately prior to joining Innocrin, Dr. Baskin-Bey served as Global Director of Oncology Development at Janssen where she led several prostate cancer development programs. Prior to Janssen, Dr. Baskin-Bey was Global Director of Oncology Development at Astellas Pharma in both Europe and the U.S., where she had responsibility for the development of six (Phase 0-4) oncology products, enzalutamide in particular.  Dr. Baskin–Bey was trained as a general surgeon at the Mayo Clinic, where she performed both basic science and clinical research through the National Institutes of Health. She received a Doctorate in Medicine from Mount Sinai/NYU and a double-major BA in Biology and Organic Chemistry from Hunter College.


Charles F. Osborne, Jr. CPA 
Chief Financial Officer and Corporate Secretary

Mr. Osborne has more than 20 years of life sciences experience, including 16 years as the Chief Financial Officer of publicly-traded or venture-backed companies. Mr. Osborne joins Innocrin following 12 years as the Chief Financial Officer at SCYNEXIS, where he led the initial public and a follow-on offering on NASDAQ. Prior experience includes NOBEX, where he raised more than $60 million of venture capital, and International Murex Technologies Co., where he ran the world-wide finance group and assisted in the sale to Abbott Laboratories. Mr. Osborne holds a B.S. in Accounting from the University of North Carolina at Chapel Hill.